An update from Immunocore Holdings (IMCR) is now available.
Immunocore Holdings plc announced promising results from its Phase 1 trial of a new cancer treatment, brenetafusp, for melanoma patients previously treated with immune checkpoints. The findings are set to be presented at the ASCO Annual Meeting and will be further discussed in a conference call and webcast. Investors and interested parties can access the webcast via the company’s website to learn about the potential impact on melanoma treatment.
For an in-depth examination of IMCR stock, go to TipRanks’ Stock Analysis page.
